GlassScriptPhysician profile
Spencer T Harmon
NPI 1356896567
$2,606.26
in general payments reported to CMS, 2019-2025
23 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $149 · 2023: $423 · 2024: $297 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,916 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.66 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $441.12 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Avadel Cns Pharmaceuticals, LLC | $390.60 | 2025 | Lumryz |
| Axsome Therapeutics, INC. | $315.97 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $280.89 | 2025 | |
| Glaxosmithkline, LLC. | $263.42 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.80 | 2021-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $118.58 | 2021-2024 | Farxiga, Breztri |
| Abbvie INC. | $113.11 | 2024-2025 | |
| Harmony Biosciences LLC | $112.49 | 2025 | |
| Inspire Medical Systems, INC. | $106.39 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $48.65 | 2022 | |
| Xeris Pharmaceuticals, INC. | $40.80 | 2021-2023 | Gvoke Hypopen |
| Fisher & Paykel Healthcare INC | $36.12 | 2025 | Fisher & Paykel Healthcare |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.30 | 2021 | |
| 3b Medical, INC. | $29.84 | 2025 | Luna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.47 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $18.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2024 | |
| Resmed Corp | $16.55 | 2025 | |
| Corium, LLC | $16.46 | 2023 | Adlarity |
| Novartis Pharmaceuticals Corporation | $13.88 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.49 | 2021 | |
| Eisai INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.